Summary
Demand in bioproducts is increasing to answer the food needs required to feed the growing population. The current manufacturing of bioproducts- vitamins, amino acids, industrial enzymes- is heavily relying on the use of fossil fuels, whereas bio-based production can save water, energy all decreasing waste and costs. The use of efficient microbial strains allows bioproduct manufacturers to do so. The optimization process of the microbial strain is going under several cycles during which culture conditions are modified, and strains genetically modified, making the development long and costly. In addition, the scale-up is often complicated.
FGen has developed a nano-reactor mimicking large bioreactor conditions allowing a high throughput screening of microbial strains, easing the scale-up and speeding the screening of the family strain respectively, all decreasing time and development costs. This nano-reactor having shown promising results, FGen aims to compile it with an innovative method to genetically modified the strains. The combination of these two methods will grant large chemical companies and biotech to save up to 3 years and around €45 M for the development of an efficient strain that will be used in the manufacturing of bioproducts. The estimated segment market for FGen is of €20 bn.
With a time to market estimated at 3 years, FGen aims to act as service provider with external companies to generate revenues and to work on the development of its own strains to license or sold them. FGen estimates to generate a positive EBITDA of €5 M at 7 years (2025), and to grow-up to more than 100 employees.
FGen has developed a nano-reactor mimicking large bioreactor conditions allowing a high throughput screening of microbial strains, easing the scale-up and speeding the screening of the family strain respectively, all decreasing time and development costs. This nano-reactor having shown promising results, FGen aims to compile it with an innovative method to genetically modified the strains. The combination of these two methods will grant large chemical companies and biotech to save up to 3 years and around €45 M for the development of an efficient strain that will be used in the manufacturing of bioproducts. The estimated segment market for FGen is of €20 bn.
With a time to market estimated at 3 years, FGen aims to act as service provider with external companies to generate revenues and to work on the development of its own strains to license or sold them. FGen estimates to generate a positive EBITDA of €5 M at 7 years (2025), and to grow-up to more than 100 employees.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/866708 |
| Start date: | 01-05-2019 |
| End date: | 31-08-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Demand in bioproducts is increasing to answer the food needs required to feed the growing population. The current manufacturing of bioproducts- vitamins, amino acids, industrial enzymes- is heavily relying on the use of fossil fuels, whereas bio-based production can save water, energy all decreasing waste and costs. The use of efficient microbial strains allows bioproduct manufacturers to do so. The optimization process of the microbial strain is going under several cycles during which culture conditions are modified, and strains genetically modified, making the development long and costly. In addition, the scale-up is often complicated.FGen has developed a nano-reactor mimicking large bioreactor conditions allowing a high throughput screening of microbial strains, easing the scale-up and speeding the screening of the family strain respectively, all decreasing time and development costs. This nano-reactor having shown promising results, FGen aims to compile it with an innovative method to genetically modified the strains. The combination of these two methods will grant large chemical companies and biotech to save up to 3 years and around €45 M for the development of an efficient strain that will be used in the manufacturing of bioproducts. The estimated segment market for FGen is of €20 bn.
With a time to market estimated at 3 years, FGen aims to act as service provider with external companies to generate revenues and to work on the development of its own strains to license or sold them. FGen estimates to generate a positive EBITDA of €5 M at 7 years (2025), and to grow-up to more than 100 employees.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
